NEUROCRINE BIOSCIENCES, INC.

Draig Therapeutics launched with $140 million in Series A funding to develop next-generation treatments for neuropsychiatric disorders, marking the largest commercial investment in Welsh research to date.

AbbVie has filed a new patent infringement lawsuit against Hetero Labs to prevent the production of generic versions of its endometriosis drug Orilissa (elagolix sodium).

Voyager Therapeutics published the first peer-reviewed study demonstrating alkaline phosphatase (ALPL) receptor's ability to transport novel AAV capsids across the blood-brain barrier in Molecular Therapy.

Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.

Phase 3 CAHtalyst pediatric study demonstrates that crinecerfont (CRENESSITY) effectively reduces glucocorticoid dosing while maintaining or improving androstenedione levels in children with classic congenital adrenal hyperplasia.

New analyses from Neurocrine Biosciences' Phase 3 CAHtalyst Pediatric study demonstrate CRENESSITY (crinecerfont) consistently reduced glucocorticoid doses while maintaining or improving androstenedione levels across all patient subgroups.

Neurocrine Biosciences has initiated a Phase 3 registrational program for NBI-1117568, an oral muscarinic M4 selective orthosteric agonist, following positive Phase 2 results in schizophrenia patients.

The sodium channel blocker market is expanding rapidly due to increasing prevalence of neuropathic pain and rising demand for selective treatments targeting Nav1.7 and Nav1.8 inhibitors.

Neurocrine Biosciences has appointed Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts who served in the role for seven years.

Neurocrine Biosciences initiates Phase 1 clinical study of NBI-1140675, a second-generation VMAT2 inhibitor, evaluating safety and pharmacokinetics in healthy adults.